≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of thymus

DOID Endpoint Browser

C3_THYMUS

thymus neoplasm: A neoplasm that affects the thymus. Representative examples include thymoma and carcinoma.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C37&
  • Cause of death: ICD-9 — 1640
  • Cancer registry: Topography ICD-O-3 — C37
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

141

4. Check minimum number of events

None

141

5. Include endpoints

None

141

6. Filter based on genotype QC (FinnGen only)

122

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 122 61 61
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 61.46 60.32 62.60

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
132
Matched controls
1320
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
75.4
65
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
21.0
64.9
61
52
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
62.6
55
*
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
58.8
52
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
835.4
57.1
52
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
25.0
54.8
43
25
GD1AD
NOMESCO Finland
Thorax CT examination
20.1
47.2
41
29
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
43.1
39
*
130
Kela drug reimbursment
Malignant tumour
+∞
39.6
36
*
H02AB02
ATC
dexamethasone; systemic
131.8
37.0
38
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
9.1
35.8
63
120
JN4BD
NOMESCO Finland
Extensive body CT
17.3
35.2
32
24
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
35.0
32
*
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
31.5
29
*
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
30.4
28
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.2
29.7
53
100
GD1AA
NOMESCO Finland
Thorax X-ray examination
9.6
29.5
107
406
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
29.3
27
*
JN4AD
NOMESCO Finland
Body CT examination
11.9
28.7
33
36
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
23.6
22
*
WX408
NOMESCO Finland
General anesthesy, balanced
5.9
22.6
63
178
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
22.5
21
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
21.4
20
*
ZXC96
NOMESCO Finland
Robot assisted procedure
233.6
20.1
20
*
N02AA05
ATC
oxycodone; systemic
6.2
19.1
41
90
A04AA01
ATC
ondansetron; systemic, rectal
30.4
19.1
25
10
WF002
NOMESCO Finland
Radical radiotherapy
220.0
19.1
19
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
220.0
19.1
19
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
18.1
17
*
L03AA13
ATC
pegfilgrastim; parenteral
206.6
18.0
18
*
A04AA02
ATC
granisetron; systemic, transdermal
206.6
18.0
18
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
206.6
18.0
18
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
206.6
18.0
18
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
6.8
17.9
33
62
B01AB05
ATC
enoxaparin; parenteral
4.7
17.4
63
214
TPH07
NOMESCO Finland
Cathetrisation of artery
6.7
17.4
32
60
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
17.0
16
*
G70.0
ICD-10 Finland
Myasthenia gravis
103.4
17.0
18
*
N07AA02
ATC
pyridostigmine; systemic
68.8
16.2
18
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
180.5
15.8
16
*
R4110
NOMESCO Finland
Physiotherapy
4.4
15.6
59
204
Z51.5
ICD-10 Finland
Palliative care
18.3
15.1
23
15
108
Kela drug reimbursment
Myasthenia gravis
90.4
14.9
16
*
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
14.9
14
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
14.9
14
*
XX3DW
NOMESCO Finland
Time consuming IT work
13.2
14.8
26
24
WX302
NOMESCO Finland
Thoracal epidural anesthesy
25.9
14.7
20
9
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.5
14.6
23
36
ZX120
NOMESCO Finland
Intravenous
7.8
14.5
22
33
WZC00
NOMESCO Finland
Treatment plan or consultation
3.9
13.6
63
248
WX402
NOMESCO Finland
General anaesthesia
4.1
12.8
48
162
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
12.7
12
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
12.7
12
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.9
12.5
51
182
B01AB04
ATC
dalteparin; parenteral
12.9
12.1
21
19
WX892
NOMESCO Finland
Monitored bed care
6.6
11.9
21
37
WZC30
NOMESCO Finland
Teaching
4.6
11.9
34
93
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
11.6
11
*
L01BC06
ATC
capecitabine; oral
+∞
11.6
11
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
11.6
11
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.6
11
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.9
11.6
45
154
L03AA02
ATC
filgrastim; parenteral
131.0
11.6
12
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
10.6
10
*
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
10.6
10
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
10.6
10
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.3
10.1
58
253
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
16.7
9.8
15
10
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
9.5
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.5
9
*
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
9.5
9
*
L01CB01
ATC
etoposide; systemic
+∞
9.5
9
*
ZXE20
NOMESCO Finland
More than three and less than five hours
4.1
9.3
29
84
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
39.6
9.2
11
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.8
8.9
22
53
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
8.3
8.8
19
26
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
29.7
8.6
11
*
JN6AD
NOMESCO Finland
CT of torso and neck
29.7
8.6
11
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
95.9
8.5
9
*
N03AX16
ATC
[U] pregabalin
3.2
8.5
44
178
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
8.4
8
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
8.4
8
*
GAA31
NOMESCO Finland
Thoracoscopy
+∞
8.4
8
*
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
8.4
8
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
8.4
8
*
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
6.5
7.6
19
33
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.7
7.6
19
46
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.4
7
*
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
+∞
7.4
7
*
116
Kela drug reimbursment
Prostate cancer
+∞
7.4
7
*
8584/3-C37.9
ICD-O-3
Thymoma, type B2 of thymus
+∞
7.4
7
*
GE1CT
NOMESCO Finland
Mediastinal biopsy with CT guidance
+∞
7.4
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.4
7
*
GD1CG
NOMESCO Finland
Extensive examination of lungs and pleura with high intensity magnet
+∞
7.4
7
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
21.5
7.2
10
5
J01MA12
ATC
levofloxacin; systemic
3.2
7.2
34
129
WW500
NOMESCO Finland
Blood transfusion
14.8
7.0
11
8
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
10.2
7.0
13
14
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.5
6.7
15
22
A02BC02
ATC
pantoprazole; systemic
2.9
6.5
101
698
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
73.2
6.5
7
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.4
6.4
17
43
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.9
6.4
15
24
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
6.3
6
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
6.3
6
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*
Z2221
NOMESCO Finland
Medical doctor
2.7
6.2
44
208
R50.9
ICD-10 Finland
Fever, unspecified
3.3
6.0
25
87

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
62
27
42.42
91.12
1.9
1.2
—
—
—
0
0
92
314
7.37
27.92
3.4
1.9
—
—
—
0
0
95
336
7.52
27.68
9.9
5.1
—
—
—
0
0
113
506
9.57
24.51
11.2
11.5
1.11
1.22
inr
2.00
93
426
34
56
7.83
21.03
11.9
9.8
25.96
24.84
mmol/l
0.83
34
56
105
483
6.74
20.65
3.8
2.3
—
—
estimate
—
0
0
117
602
9.30
20.00
20.8
6.6
3.93
4.16
e9/l
0.71
101
515
32
56
7.22
18.61
2.4
1.8
2.01
2.33
ug/l
0.49
22
42
105
510
6.18
18.56
13.7
6.2
1.20
1.21
mmol/l
0.49
96
450
110
559
6.81
18.31
10.5
5.4
0.62
0.56
e9/l
1.56
92
474
111
570
6.95
18.21
10.7
5.4
1.72
1.85
e9/l
0.29
93
501
112
582
7.10
18.05
12.0
5.6
0.14
0.20
e9/l
5.07
94
505
110
563
6.72
18.04
10.6
5.4
0.04
0.04
e9/l
0.55
92
479
72
268
4.71
17.67
5.5
3.7
—
—
—
0
0
33
63
6.65
17.61
16.0
10.8
0.55
0.68
%
1.24
33
63
34
67
6.49
17.58
1.1
1.7
—
—
—
0
0
46
124
5.16
16.84
12.4
8.0
5.53
5.18
kpa
1.58
46
118
46
124
5.16
16.84
12.5
8.0
14.00
11.32
kpa
1.66
46
119
82
347
4.60
16.74
2.5
1.6
—
—
—
0
0
46
125
5.11
16.66
12.4
8.0
7.41
7.42
ph
0.14
15
74
33
67
6.23
16.49
16.0
10.4
1.02
1.45
%
1.31
33
67
49
143
4.86
16.23
12.1
6.4
104.24
104.08
mmol/l
0.08
49
143
37
88
5.45
15.55
16.4
9.0
—
—
—
0
0
37
90
5.32
15.13
1.4
1.0
—
—
—
0
0
75
324
4.04
14.27
14.6
4.2
—
—
—
0
0
44
140
4.21
12.69
1.3
1.6
—
—
—
0
0
72
324
3.69
12.47
9.1
1.9
2.36
2.35
mmol/l
0.23
67
288
69
306
3.63
12.15
6.8
3.1
7.40
7.40
ph
0.07
50
210
91
489
3.77
11.72
19.8
9.0
0.00
0.00
e9/l
0.49
73
391
48
173
3.79
11.48
1.7
1.9
—
—
—
0
0
64
296
3.26
10.11
3.7
2.8
0.13
0.29
e6/l
1.26
50
204
36
117
3.86
9.86
1.2
1.6
—
—
—
0
0
45
170
3.50
9.85
3.6
2.9
2.86
2.94
e6/l
0.01
26
76
39
138
3.59
9.39
2.2
2.5
21.99
24.34
%
0.43
39
127
61
298
2.95
8.43
1.5
1.4
—
—
—
0
0
67
347
2.89
8.27
3.7
2.8
65.11
38.06
e6/l
0.27
54
253
72
396
2.80
7.81
4.6
3.5
82.78
45.36
e6/l
0.25
54
264
53
261
2.72
6.96
2.0
2.0
2.79
2.64
mg/l
0.17
47
223
42
187
2.83
6.65
2.0
2.4
548.76
560.91
mosm/kgh2o
0.12
37
160
36
150
2.92
6.42
2.4
1.9
—
—
—
0
0
6
0
+∞
6.29
2.3
0.0
21.50
—
u/ml
—
6
0
9
6
15.96
5.99
1.7
1.0
11.78
12.50
%
—
9
6
49
248
2.55
5.94
2.3
1.7
1.22
0.85
mg/l
0.84
41
196
9
7
13.67
5.67
2.3
1.3
0.40
1.33
e9/l
—
9
7
9
8
11.95
5.37
2.4
1.9
32.94
52.06
%
—
9
8
9
10
9.55
4.86
2.9
2.1
—
—
—
0
0
19
65
3.25
4.67
3.4
1.4
—
—
—
0
0
7
6
12.22
4.32
2.3
1.0
—
—
—
0
0
7
6
12.22
4.32
6.6
6.7
—
—
—
0
0
33
159
2.43
4.30
1.4
1.4
688.00
625.56
titre
—
10
36
27
119
2.60
4.23
2.1
2.1
7.22
9.59
umol/l
0.28
27
106
10
18
5.92
4.06
1.3
1.2
2.00
5.91
u/ml
—
5
11
9
15
6.35
3.89
1.3
1.1
—
—
—
0
0
6
5
12.48
3.80
2.3
1.0
23.67
331.60
e6/l
—
6
5
56
354
2.01
3.66
2.8
2.3
63.38
69.38
u/l
0.17
56
328
22
94
2.61
3.65
6.7
2.3
53.78
63.08
e9/l
0.56
13
65
30
149
2.31
3.62
3.0
1.5
—
—
—
0
0
66
458
1.88
3.16
4.1
3.4
43.17
40.44
ng/l
0.04
54
309
41
245
1.98
3.06
3.3
3.7
121.35
365.57
ng/l
0.99
34
192
24
117
2.28
3.00
3.9
3.4
7.37
7.38
ph
—
9
71
5
5
10.32
3.00
2.2
3.8
779.60
551.60
u/ml
—
5
5
112
937
2.29
3.00
43.3
15.3
14.29
13.46
%
4.85
112
929
13
47
2.96
2.91
1.1
1.2
—
—
—
0
0
16
66
2.62
2.83
2.8
4.8
—
—
—
0
0
14
54
2.78
2.80
2.9
1.5
22.38
5.79
iu/ml
—
8
13
78
589
1.79
2.70
3.6
3.5
0.00
0.00
estimate
-0.00
18
108
9
25
3.78
2.63
1.2
1.1
—
—
—
0
0
12
44
2.90
2.62
4.8
2.2
—
—
—
0
0
6
11
5.65
2.57
1.0
1.0
—
—
—
0
0
79
607
1.75
2.50
3.6
3.5
0.00
0.00
estimate
-0.00
18
102
78
599
1.74
2.46
3.5
3.5
0.00
0.00
estimate
-0.00
17
111
16
72
2.39
2.39
6.9
4.4
93.75
94.15
ng/l
0.01
16
65
17
80
2.29
2.30
1.5
1.3
21.06
369.47
u/ml
2.01
12
75
6
13
4.78
2.30
3.3
2.5
3.94
4.71
e9/l
—
6
13
6
13
4.78
2.30
1.8
2.2
3.72
2.50
u/ml
—
6
13
6
13
4.78
2.30
1.2
1.2
—
—
—
0
0
43
286
1.75
2.22
2.7
3.1
—
—
—
0
0
6
14
4.43
2.17
2.2
1.1
—
—
—
0
0
6
14
4.43
2.17
2.2
1.1
—
—
—
0
0
6
14
4.43
2.17
2.2
1.1
—
—
—
0
0
6
14
4.43
2.17
2.2
1.1
—
—
—
0
0
37
240
1.75
2.07
1.2
1.3
942.91
29.92
iu/ml
0.48
11
71
6
15
4.14
2.06
1.3
2.4
—
—
—
0
0
37
241
1.74
2.04
2.0
1.3
2.12
2.56
g/l
0.88
29
136
7
21
3.46
1.99
1.0
1.2
—
—
—
0
0
7
21
3.46
1.99
1.6
1.4
—
—
—
0
0
6
16
3.87
1.96
1.0
1.6
0.18
0.17
nmol/l
—
6
10
6
16
3.87
1.96
3.3
2.2
62.33
59.37
%
—
6
16
126
1170
2.69
1.92
24.3
11.2
—
—
—
0
0
8
28
2.97
1.89
2.0
2.4
25.46
24.29
mmol/l
—
8
28
5
12
4.28
1.84
3.0
1.5
181.86
26.39
ng/l
—
5
12
5
12
4.28
1.84
1.2
1.9
8.48
12.14
%
—
5
12
63
482
1.59
1.84
3.3
3.3
6.28
6.26
ph
0.03
32
268
6
18
3.44
1.76
1.0
1.1
—
—
—
0
0
5
13
3.95
1.73
1.0
1.7
—
—
nmol/l
—
0
0
15
76
2.10
1.72
4.6
3.9
0.30
0.18
%
—
5
17
6
19
3.26
1.68
1.0
1.0
—
—
—
0
0
6
20
3.09
1.60
1.3
1.9
—
—
—
0
0
16
87
1.95
1.54
1.1
1.3
—
—
—
0
0
5
15
3.42
1.53
1.6
2.3
4.90
5.08
kpa
—
5
15
5
15
3.42
1.53
1.6
2.3
8.60
8.45
kpa
—
5
15
6
21
2.94
1.52
1.0
1.9
7.50
8.12
kpa
—
6
21
22
134
1.77
1.51
1.5
1.4
—
—
—
0
0
15
81
1.96
1.47
4.8
4.1
0.00
0.00
%
—
5
15
6
22
2.81
1.45
4.3
3.3
7.41
7.40
ph
—
6
22
6
22
2.81
1.45
1.0
1.2
—
—
—
0
0
15
83
1.91
1.38
1.8
1.7
—
—
—
0
0
8
34
2.44
1.31
1.1
1.2
—
—
—
0
0
20
124
1.72
1.30
1.9
1.8
—
—
—
0
0
5
18
2.84
1.29
12.0
2.6
—
—
—
0
0
17
101
1.78
1.27
3.6
2.0
318.65
386.14
nmol/l
1.03
17
95
14
78
1.89
1.27
2.9
3.7
226.36
164.60
ng/l
0.45
14
73
42
316
1.48
1.24
3.8
3.4
0.00
0.00
estimate
-0.00
14
103
42
535
0.68
1.20
1.8
2.0
1.38
1.36
mmol/l
0.05
37
458
13
72
1.89
1.20
2.1
3.1
—
—
—
0
0
61
505
1.39
1.04
1.9
2.0
92.77
95.57
pmol/l
0.24
39
250
112
1186
0.63
0.99
5.0
6.0
2.74
2.71
mmol/l
0.12
107
1115
9
50
1.86
0.99
2.6
4.5
0.96
0.91
%
—
9
45
32
245
1.40
0.85
9.7
4.4
—
—
—
0
0
8
47
1.75
0.82
1.4
1.1
46.34
25.27
iu/l
—
8
41
21
149
1.49
0.82
2.6
2.0
121.80
89.33
ug/g
0.26
21
120
11
66
1.73
0.81
3.8
3.3
1.22
1.22
mmol/l
0.11
11
56
95
864
1.36
0.80
3.6
3.9
15.08
14.78
pmol/l
0.48
89
795
8
134
0.57
0.78
1.4
1.4
—
—
—
0
0
9
54
1.71
0.76
1.2
2.4
0.59
0.57
%
—
9
54
9
56
1.65
0.74
1.2
2.3
1.13
1.24
%
—
9
56
5
25
2.04
0.73
1.4
1.9
—
—
—
0
0
5
27
1.88
0.69
2.0
1.1
16.64
4.75
u/l
—
5
22
5
28
1.82
0.67
3.0
4.2
3.86
3.90
mmol/l
—
5
28
11
72
1.58
0.61
1.8
1.5
—
57.63
—
0
8
112
1170
0.72
0.60
4.3
5.2
4.67
4.60
mmol/l
0.28
106
1100
112
1168
0.73
0.56
4.3
5.0
1.44
1.44
mmol/l
0.06
107
1092
20
152
1.37
0.56
1.5
1.2
—
—
—
0
0
27
216
1.31
0.55
1.3
1.4
0.97
8.84
u/ml
—
6
85
46
398
1.24
0.51
3.7
3.3
—
—
—
0
0
7
47
1.52
0.48
3.6
3.6
36.79
36.85
°c
—
7
47
41
469
0.82
0.45
2.7
3.4
—
—
—
0
0
37
317
1.23
0.45
2.3
3.0
0.00
0.00
estimate
-0.00
12
89
8
57
1.43
0.43
1.1
1.3
—
—
—
0
0
118
1138
1.35
0.43
4.7
4.8
5.82
5.98
mmol/l
0.90
111
1061
7
101
0.68
0.41
1.3
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.49
0.41
1.0
1.3
423.40
455.41
mg/l
—
5
34
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
107
1111
0.81
0.37
3.7
4.3
1.29
1.31
mmol/l
0.07
102
1030
28
240
1.21
0.34
3.6
2.6
0.91
0.75
ug/l
0.43
20
143
7
52
1.37
0.32
2.1
2.4
—
—
—
0
0
49
446
1.16
0.30
3.2
3.3
0.00
0.00
estimate
-0.00
15
94
14
112
1.28
0.29
1.4
1.3
—
—
—
0
0
8
62
1.31
0.28
3.0
3.9
4.24
4.57
pmol/l
—
8
57
6
85
0.69
0.24
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
8.88
—
0
10
0
12
0.00
0.21
0.0
1.2
—
178.35
—
0
12
0
13
0.00
0.21
0.0
2.8
—
4.18
—
0
13
0
13
0.00
0.21
0.0
2.8
—
1.19
—
0
13
0
13
0.00
0.21
0.0
2.8
—
105.15
—
0
13
24
269
0.87
0.20
1.3
1.3
0.89
1.02
u/ml
—
7
67
0
14
0.00
0.20
0.0
2.3
—
—
—
0
0
39
421
0.90
0.19
3.4
3.5
64.48
53.84
mg/l
0.13
28
281
40
425
0.92
0.14
3.9
4.1
11.89
8.66
mg/mmol
0.20
25
282
5
48
1.04
0.09
1.2
1.7
—
—
—
0
0
9
103
0.86
0.06
1.4
1.4
—
—
—
0
0
26
272
0.95
0.05
3.9
3.8
1.02
1.02
kg/l
0.21
18
169
13
124
1.05
0.00
1.6
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
92.92
—
0
6
0
6
0.00
0.00
0.0
1.5
—
18.52
—
0
6
0
9
0.00
-0.00
0.0
10.3
—
0.67
—
0
9
0
8
0.00
-0.00
0.0
1.5
—
7.76
—
0
8
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
176.83
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
45.80
—
0
5

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_THYMUS – Malignant neoplasm of thymus

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).